ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Total Liabilities : $722.9 Mil (As of Sep. 2016)

View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals Total Liabilities?

ARIAD Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2016 was $722.9 Mil.

ARIAD Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2016 ($656.56 Mil) to Jun. 2016 ($662.26 Mil) and increased from Jun. 2016 ($662.26 Mil) to Sep. 2016 ($722.94 Mil).

ARIAD Pharmaceuticals's annual Total Liabilities increased from Dec. 2013 ($185.38 Mil) to Dec. 2014 ($522.32 Mil) and increased from Dec. 2014 ($522.32 Mil) to Dec. 2015 ($649.83 Mil).

ARIAD Pharmaceuticals Total Liabilities Historical Data

The historical data trend for ARIAD Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARIAD Pharmaceuticals Total Liabilities Chart

ARIAD Pharmaceuticals Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Total Liabilities

Get a 7-Day Free Trial

100.57

67.34

185.38

522.32

649.83

ARIAD Pharmaceuticals Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Total Liabilities	Get a 7-Day Free Trial															625.79	649.83	656.56	662.26	722.94

ARIAD Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ARIAD Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2015 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	132.284	+	(429.22	+	11.244
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	77.085	+	0)
	=	649.8

Total Liabilities	=	Total Assets (A: Dec. 2015 )	-	Total Equity (A: Dec. 2015 )
	=	546.692	-	-103.141
	=	649.8

ARIAD Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2016 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	110.843	+	(522.905	+	1.2789769243682E-13
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	89.192	+	0)
	=	722.9

Total Liabilities	=	Total Assets (Q: Sep. 2016 )	-	Total Equity (Q: Sep. 2016 )
	=	676.591	-	-46.349
	=	722.9

ARIAD Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ariad.com

ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan	officer: Sr. V. P. - General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni	officer: EVP, CFO & Treasurer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson	officer: President, R&D, CSO	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag	officer: Sr. VP, Reg. Affairs & Quality	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole	officer: SVP, Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos	director, officer: President and CEO	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli	director	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall	officer: EVP, CCO	MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska	officer: SVP, Clinical R&D, CMO	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines

From GuruFocus

ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 03-15-2011

ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-10-2009